Darunavir

115 interactions 11 explained in plain English
Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jul 4, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Lovastatin Lurasidone Ivabradine Methylergonovine Colchicine Maraviroc
13 Contraindicated 89 Major 13 Moderate
All (115) Contraindicated (13) Major (89) Moderate (13)

Moderate

Darunavir Trospium / Xanomeline Cobenfy Explained Increased oral sensitive CYP3A4 substrate exposure and an increased risk on severity and frequency of sensitive CYP3A4 substrate-r... Details Darunavir Canagliflozin Invokana Worsening glycemic control Details Darunavir Dabigatran Pradaxa® Increased dabigatran etexilate exposure Details Darunavir Dabigatran Etexilate Increased dabigatran etexilate exposure Details Darunavir Disopyramide Norpace Increased antiarrhythmic exposure and an increased risk of antiarrhythmic-related adverse effects Details Darunavir Dofetilide Tikosyn Increased antiarrhythmic exposure and an increased risk of antiarrhythmic-related adverse effects Details Darunavir Felodipine Plendil® Increased calcium channel blockers/CYP3A substrates exposure and an increased risk of calcium channel blockers/CYP3A substrates-re... Details Darunavir Flecainide Tambocor® Increased antiarrhythmic exposure and an increased risk of antiarrhythmic-related adverse effects Details Darunavir Linagliptin Tradjenta Worsening glycemic control Details Darunavir Mexiletine Mexitil® Increased antiarrhythmic exposure and an increased risk of antiarrhythmic-related adverse effects Details Darunavir Nateglinide Starlix® Altered glycemic control Details Darunavir Nifedipine Adalat® Increased calcium channel blockers/CYP3A substrates exposure and an increased risk of calcium channel blockers/CYP3A substrates-re... Details Darunavir Nisoldipine Sular Increased calcium channel blockers/CYP3A substrates exposure and an increased risk of calcium channel blockers/CYP3A substrates-re... Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.